Real-world experience with abiraterone in metastatic castration-resistant prostate cancer

Aim: To evaluate abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: This is a multicenter retrospective analysis, involving 44 consecutive abiraterone-treated mCRPC patients, in either chemotherapy-naive or postdocetaxel setting. Results: The study cohort&...

Full description

Bibliographic Details
Main Authors: Yasar Ahmed, Nemer Osman, Rizwan Sheikh, Sarah Picardo, Geoffrey Watson
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Cancer Translational Medicine
Subjects:
Online Access:http://www.cancertm.com/article.asp?issn=2395-3977;year=2017;volume=3;issue=4;spage=133;epage=138;aulast=Ahmed